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Abstract
Both the non-receptor tyrosine kinase, c-Src, and members of the epidermal growth factor
(EGF) receptor family are overexpressed in high percentages of human breast cancers.
Because these molecules are plasma membrane-associated and involved in mitogenesis, it
has been speculated that they function in concert with one another to promote breast
cancer development and progression. Evidence to date supports a model wherein c-Src
potentiates the survival, proliferation and tumorigenesis of EGF receptor family members, in
part by associating with them. Phosphorylation of the EGF receptor by c-SRC is also critical
for mitogenic signaling initiated by the EGF receptor itself, as well as by several G-protein
coupled receptors (GPCRs), a cytokine receptor, and the estrogen receptor. Thus, c-Src
appears to have pleiotropic effects on cancer cells by modulating the action of multiple
growth-promoting receptors.
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EGF = epidermal growth factor; ER = estrogen receptor; ERK = extracellular-signal-regulated kinase; GPCRs = G-protein-coupled receptors;
HER = human epidermal growth factor receptor; JAK = janus kinase; LPA = lysophosphatidic acid; MAPK = mitogen-activated protein kinase;
STAT = signal transducer and activator of transcription; PI-3K = phosphatidyl inositol-3 kinase.
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Introduction
Recent evidence has implicated an involvement of tyrosine
kinases in human breast cancer development. Two fami-
lies in particular have been examined, namely, the human
epidermal growth factor and the Src families of tyrosine
kinases.
Human epidermal growth factor receptor
(HER1) in human breast cancer
The human epidermal growth factor receptor (HER1) is the
prototype of a family that consists of four known members
(EGF receptor/HER1, neu/erbB2/HER2, erbB3/HER3,
and erbB4/HER4). These receptor tyrosine kinases are
characterized by an extracellular ligand-binding domain, an
internal kinase domain, and a carboxyl-terminal domain that
contains multiple tyrosine residues. Upon binding of EGF,
HER1 dimerizes and becomes phosphorylated on these c-
arboxyl-terminal tyrosyl residues, which in turn act as
docking sites for multiple signaling proteins that contain
SH2 domains. HER1 plays a variety of roles in normal
development, and is found in ductal epithelial cells of
normal breast tissue [1••].
The link between HER1 and human cancer initally came
from studies by Velu et al [2], who demonstrated that cells
that overexpress HER1 become transformed when they
are grown in the continuous presence of EGF. HER1 is
overexpressed in a variety of human cancers, includingBreast Cancer Research    Vol 2 No 3 Biscardi et al
benign skin hyperplasia, glioblastoma and cancers of the
breast, prostate, ovary, liver, bladder, esophagus, larynx,
stomach, colon, and lung [3•]. Approximately 30% of
human breast tumors overexpress HER1, and this over-
expression is correlated with a loss of estrogen respon-
siveness and a poorer prognosis [4,5]. Much evidence
suggests that HER1 is involved in later stages of human
breast cancer and may play a role in the metastatic
process [6].
Human epidermal growth factor receptor 2
(HER2) in breast cancer
Among the HER family members, HER2 is most closely
related to HER1 [7] and has been found to be amplified
in 10–35% of human breast carcinomas, an event that
portends a poor disease prognosis [8••,9]. Overexpres-
sion of HER2 occurs more frequently in the early stages
of breast cancer, and is therefore thought to be involved
in tumor initiation and early stages of progression [10••].
The involvement of HER2 in human breast cancer is
further supported by the success of recent immunother-
apy trials, which targeted the receptor in conjunction
with current chemotherapeutic protocols [11].
c-Src in breast cancer
c-Src, a nonreceptor tyrosine kinase that is localized to
intracellular membranes of the cell, has also been found to
be overexpressed or highly activated in a number of human
neoplasms, including carcinomas of the breast, lung, colon,
esophagus, skin, parotid, cervix, and gastric tissues, as well
as in neuroblastomas and myeloproliferative disorders. In
several studies that together examined over 125 human
breast tumor specimens and cell lines [12,13,14•], more
than 70% of the samples contained levels of c-Src tyrosine
kinase activity that were two-fold to 50-fold greater than
those found in normal breast epithelium or immortalized
mammary epithelial cells. This elevated activity could be
accounted for solely by an increase in c-Src protein levels,
and did not reflect an increase in specific activity of the
enzyme [14•]. Such striking increases in c-Src protein
levels in a surprisingly high percentage of human breast
neoplasias provide correlative evidence that c-Src is
involved in some facet of breast cancer development.
Unlike the EGF receptor, overexpression of c-Src alone is
insufficient to transform murine fibroblasts in culture or to
sustain tumor growth in intact animals [15,16,17••].
However, expression of dominant interfering forms of
c-Src (Fig. 1) in cultured murine fibroblasts has shown that
c-Src is required for EGF-induced mitogenesis [18•,19],
and studies in transgenic mice have demonstrated that
c-Src is necessary for induction of mammary tumors by
the polyomavirus middle T oncogene [20]. These findings
suggest that c-Src may function to promote growth of
tumor cells by participating in or augmenting mitogenic
signaling pathways that are initiated by extracellular
growth factors or intracellular oncogenes. There appear to
be two prominent roles of c-Src in this regard. One is to
modulate receptor function by augmenting signals immedi-
ately downstream of the receptors and by regulating endo-
cytosis [1••,21••,22••], and the other is to affect
morphogenetic remodeling of the cell by phosphorylating
proteins that associate with the actin cytoskeleton
[23,24•].
Synergism between c-Src and human
epidermal growth factor receptor 1 in
oncogenesis
The fact that c-Src and HER1 are co-overexpressed in
many of the same tumor types suggests that these two
kinases may participate in regulating the genesis and/or
progression of human cancers. In a direct test to resolve
this question, dual overexpression of both c-Src and
HER1 in C3H10T½ mouse fibroblasts was found to lead
to synergistic increases in EGF-induced DNA synthesis,
soft agar colony formation, and tumor formation in nude
mice, when compared with cells that express only one of
the pair [17••]. This enhanced oncogenesis correlated with
the EGF-dependent physical association between c-Src
and HER1, increased phosphorylation of the HER1 sub-
strates, Shc and phospholipase Cg, and the phosphoryla-
tion of two novel tyrosyl residues on the receptor, which
have been identified by phosphotryptic mapping to be Tyr
845 and Tyr 1101 [17••,24•]. Stover et al [25] showed
that activated Src can phosphorylate HER1 at Tyr 891
and Tyr 920 in vitro, and that these sites can mediate
binding of the SH2 domains of phosphatidyl inositol-3
kinase (PI-3K) and Src itself. These same sites have been
Figure 1
Structure of c-Src. C-Src is the prototype of a large family of
cytoplasmic tyrosine kinases that associate with cellular membranes
through lipid modifications at their amino-termini. As a linear molecule,
the relationship between the various domains can be seen: an amino-
terminal membrane-association domain that contains the site of
myristylation; a unique domain that exhibits the widest sequence
divergence among family members of any of the domains; an SH3
domain that binds polyproline motifs on target molecules; a SH2
domain that binds phosphotyrosine residues on target molecules; a
SH2/kinase linker; the catalytic domain; and the negative regulatory
domain that contains the predominant site of tyrosine phosphorylation
on the inactive molecule (Y527 in chicken, Y530 in human). Mutations
that abrogate myristylation, the SH2 domain, and the catalytic activity
were shown to reduce EGF-stimulated DNA synthesis in C3H10T½
murine fibroblasts, providing evidence for the involvement of c-Src in
mitogenic pathways [18•].
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found to be phosphorylated in several colorectal carcino-
mas and MCF7 breast cancer cells, from which c-Src and
PI-3K can be coimmunoprecitated with HER1. These find-
ings support the idea that bidirectional interactions
between c-Src and HER1 occur.
Interestingly, co-overexpression of both HER1 and c-Src
also occurs in a subset of human breast cancer cell lines
and breast tumor tissues [14•]. Like the mouse 10T½
fibroblasts, breast tumor cell lines that co-overexpress
c-Src and HER1 display EGF-induced complex formation
between c-Src and HER1, the appearance of Tyr 845 and
Tyr 1101 phosphorylations on the c-Src-associated
receptor, and increased phosphorylation of the HER1
effectors Shc and mitogen-activated protein kinase
(MAPK), as well as increased tumor size in nude mice
when compared with the majority of cell lines that do not
overexpress these tyrosine kinases or express only one of
the pair. Enhanced MAPK and MEK activity have also
been found in human breast tumors that overexpress both
c-Src and HER1 [26,27]. These results suggest that c-Src
and HER1 act synergistically, and that this interaction is
manifested by increased signaling through HER1, unregu-
lated growth, and tumorigenesis. Because complex forma-
tion between HER1 and c-Src can be detected only under
conditions of mutual overexpression, as is seen in many
breast tumors and cell lines, disruption of this complex
could provide the basis for novel therapeutic approaches.
Molecular mechanisms of c-Src/human
epidermal growth factor receptor 1 synergism
Although little is known about the biologic significance
of Tyr 1101 phosphorylation, Tyr 845 is located in the
activation loop of the catalytic domain and is particularly
intriguing, because its homologs are found in a variety
of receptor and nonreceptor tyrosine kinases (Fig. 2)
[28]. In fact, substitution of Phe for the Tyr 845
homologs in other receptors renders these receptors
catalytically impaired and defective in downstream sig-
naling [29–31]. In contrast, Tyr 845 in the EGF receptor
has never been identified as an autophosphorylation
site. Failure to detect such a phosphorylation was inter-
preted to mean either that the site was not phosphory-
lated or that its phosphorylation was extremely short-lived.
Recently, it was shown [32••] that phosphorylation of Tyr
845 is dependent upon the catalytic activity of c-Src, sug-
gesting that c-Src directly phosphorylates this site. Cells
expressing kinase-inactive c-Src not only fail to support
phosphorylation of Tyr 845, but also display a drastically
decreased ability to grow in soft agar in the presence of
EGF and to form tumors in nude mice, suggesting that
phosphorylation of Tyr 845 may be critical for mitogenesis
and transformation. Indeed, in 10T½ cells that express
either increased or endogenous levels of c-Src, expres-
sion of a Tyr845Phe mutant form of HER1 results in a
reduction in EGF-, serum-, and lysophosphatidic acid
(LPA)-induced DNA synthesis [24•,32••]. Thus, c-Src-
mediated phosphorylation of Tyr 845 appears to be nec-
essary for the mitogenesis that emanates from HER1.
The finding that serum- and LPA-induced DNA synthesis
are affected by the Tyr845Phe mutation suggests that
other cell-surface receptors may mediate their effects in
part through the EGF receptor. LPA, a major mitogen in
serum, is known to activate a Gi-coupled receptor [33].
Several laboratories have recently reported that activation
of certain GPCRs can trigger phosphorylation of the EGF
Figure 2
Tyr 845 is located in the catalytic domain of HER1 in a highly
conserved subdomain that has functional homologs in other tyrosine
kinases. Tyr 845 resides in the activation loop of the HER1 tyrosine
kinase catalytic domain (upper panel), a region that shares a high
degree of homology among all tyrosine kinases (lower panel). Upon
ligand-binding to the EGF receptor (EGFR), the activation loop
containing phosphorylated Tyr 845 is modeled (upper panel [63]) to
flip into a configuration that promotes access to ATP and substrate, as
is the case with phosphorylation of the analogous tyrosines within
other tyrosine kinases. Mutation of sites in other tyrosine kinases that
are analogous to Tyr 845 renders the molecules catalytically inactive
and abrogates downstream biologic signaling. Similar effects of
mutagenizing Tyr 845 have been observed [24•,32••]. A unique
characteristic of Tyr 845 appears to be that its phosphorylation is
mediated by c-Src, whereas homologs in other receptor tyrosine
kinases are phosphorylated by the receptors themselves. The
phosphorylation of Tyr 845 by c-Src is proposed to facilitate cross-talk
between HER1 and signaling pathways activated by other cellular
receptors, such as G-protein-coupled receptors and estrogen
receptor.
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c-Src: Y416receptor, as well as activation of its downstream effectors
Shc and MAPK, and that this activation is dependent on
c-Src kinase activity [34•,35,36]. In addition, stimulation of
the growth hormone cytokine receptor has been found to
induce EGF receptor phosphorylation via janus kinase 2
[37]. Recent work in our laboratory (Biscardi et al, unpub-
lished data) has demonstrated that treatment of 10T½
cells with different GPCR ligands (thrombin, endothelin,
and LPA) or with growth hormone induces increases in
overall tyrosine phosphorylation of HER1, as well as in Tyr
845 phosphorylation. Interestingly, the kinase activity of
c-Src is also required for phosphorylation of Tyr 845 via
these alternate receptors, and mitogenesis is dependent
on the phosphorylation of Tyr 845. 10T½ cells that express
the Tyr845Phe variant of HER1 are impaired in their ability
to synthesize DNA in response to these stimuli. However,
the weakly mitogenic effects of isoproterenol, which
signals through a Gsa-coupled pathway, are not affected
by the Tyr845Phe mutation, indicating that this mutation
does not act as a general inhibitor of mitogenesis.
Estrogen receptor, c-Src, and human
epidermal growth factor receptor 1
Accumulating evidence also points to an intricate network
of cross-talk between the estrogen receptor and HER1.
Early work by Ignar-Trowbridge et al [38,39] demonstrated
that EGF can transcriptionally activate genes that contain
estrogen response elements. More recently, Migliaccio et al
[40,41] showed that estrogen is able to activate many of
the effectors classically thought to be linked to the EGF
receptor signaling pathway, including c-Src, Ras, and
MAPK. These researchers have also shown that estrogen
requires c-Src kinase activity in order to trigger its mitogenic
effects [42••]. To further investigate this phenomenon, our
laboratory has examined the effects of the Tyr845Phe muta-
tion on estrogen-dependent DNA synthesis in the estrogen-
responsive MCF7 breast cancer cell line. As was the case
for the GPCR and cytokine receptor coupled agonists,
estrogen-stimulated DNA synthesis was decreased to basal
levels as a result of expression of the Y845F mutant (Bis-
cardi et al, unpublished data). Taken together, these find-
ings suggest the possibility that the EGF receptor plays an
important, perhaps widespread, role in mediating the cell’s
response to an array of external signals and that the c-Src
mediated phosphorylation of EGF receptor Tyr 845 appears
to be a critical event in this process (Fig. 3).
Human epidermal growth factor receptor 2 and
c-Src in breast cancer
Evidence supporting bidirectional interactions between
c-Src and the EGF receptor raises the question of
whether c-Src interacts in a similar manner with other HER
family members. Some indications that HER2 and c-Src
can physically and/or functionally interact have emerged
over recent years, but little is currently known about the
relationship between c-Src and either HER3 or HER4. In
vitro studies have also demonstrated that HER2/neu can
associate with the SH2 domain of c-Src in a tyrosine
phosphorylation-dependent manner [43,44••], and in vivo
coassociation between HER2/neu and c-Src has been
detected in murine mammary tumors, human breast
cancer cell lines, and human tumor tissues [44••]
(Belsches-Jablonski AP et al. unpublished data). Further-
more, transgenic murine tumor tissues or human mammary
epithelial cell lines expressing mutationally activated Neu
exhibit a correlative increase in c-Src activity [44••,45].
These results suggest that c-Src may be downstream of
HER2 signaling. It has also been demonstrated in vitro
[25], however, that c-Src is able to phosphorylate HER2
at nonautophosphorylation sites. The identity of these
sites, their existence in intact cells, and their functional sig-
nificance have not yet been determined. Nevertheless, the
currently available information suggests that HER2 and
c-Src are able to interact physically and that bidirectional
signaling may be a mechanism of interaction between
these two tyrosine kinases, as it is for HER1 and c-Src.
The functional consequences of coassociation between
HER2 and c-Src remain unclear. In fact, available evidence
suggests that the HER2–c-Src interaction may affect dif-
ferent parameters of oncogenesis to different extents and
perhaps by different mechanisms than the HER1–c-Src
association. Results from recent studies of MCF10A cells
that ectopically express mutationally activated rat p185neu
[45], and a panel of 13 human breast cancer cell lines and
13 human mammary tumor samples (Belsches-Jablonski
AP et al. unpublished data) suggest that the HER2–c-Src
complex may play an important role in heregulin-stimulated
anchorage-independent growth and antiapoptotic or sur-
vival mechanisms, but have less of an effect on anchorage-
dependent growth. In contrast, the HER1–c-Src complex
has been found to have striking effects on anchorage-
dependent growth and on anchorage-independent growth,
but its role in survival signaling is unclear.
Whether c-Src mediates the phosphorylation of the
Tyr 845 homolog in HER2 (Tyr 877) as it does in HER1 is
not known. The comparable site in the activated, rat
p185neu protein (Tyr 882) is an autophosphorylation site,
and mutation of this residue reduces the intrinsic kinase
activity of the protein and its transforming potential [46•].
These findings suggest that the Tyr 845 homolog in
p185neu or HER2 functions in a manner more similar to the
majority of tyrosine kinase receptors than it does to HER1,
and raise the possibility that the mechanism by which c-
Src interacts with HER2 may be distinct from that by
which c-Src interacts with HER1.
Signals activated by c-Src/human epidermal
growth factor receptor 1 interactions
Although mutation of Tyr 845 has profound effects on the
cell’s ability to respond mitogenically to EGF, many of the
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mutant HER1 kinase activity appears to be unchanged, as
does its ability to associate with c-Src. Moreover, the
phosphorylation and/or activation of a number of HER1
effectors, including Shc, MAPK, signal transducer and
activator of transcription (STAT)3, and phospholipase Cg
[32••] (Tice and Biscardi, unpublished data) are likewise
unaffected. However, recent evidence, produced in a col-
laborative effort between our laboratory and that of Silva
(unpublished data), suggests that STAT5b might be a
physiologically relevant downstream effector of Tyr845.
The STATs are a family of transcription factors that are acti-
vated at the plasma membrane by tyrosine phosphorylation
in response to signals from cytokine and growth factor
receptors [47•,48]. Tyrosine phosphorylation results in STAT
dimerization, nuclear translocation, and binding of STAT
dimers to consensus elements upstream of regulated genes.
Increasing evidence indicates that STAT proteins are
involved in the process of oncogenesis [49•,50]. Two lab-
oratories have shown that STAT3 is required for v-Src
transformation [51••,52••], whereas deGroot et al [53]
demonstrated that active STAT5 is necessary for the soft
agar growth of BCR-Abl transformed leukemia cells.
Recent studies [54••] have also indicated a direct role for
c-Src in the activation of STAT proteins. For example,
c-Src was shown to mediate the EGF stimulation of
STATs 1, 3, 5a, and 5b in NIH3T3 cells engineered to
overexpress HER1, as well as in A431 cells, which
endogenously express high levels of HER1. In contrast,
another group [55] has recently described a role for c-Src
in the tyrosine phosphorylation (but not the transcriptional
activation) of STAT5a and STAT5b in a COS cell transfec-
tion model.
Our recent studies (Silva et al, unpublished data) indicate
a role for the STAT proteins in signaling pathways that are
activated in 10T½ and breast cancer cells co-overex-
pressing c-Src and EGF receptor. We have shown that
c-Src tyrosine kinase activity is required for maximal tran-
scriptional activation of STAT5b by EGF, and that phos-
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Figure 3
HER1 acts as a central mediator for multiple signaling pathways. A variety of extracellular ligands trigger the phosphorylation of HER1 on Tyr 845.
These include the following: thrombin, endothelin, and LPA, which bind G-protein coupled receptors; growth hormone, which binds a cytokine
receptor; and estrogen, which binds a steroid hormone receptor. Moreover, c-Src kinase activity is required for the ability of LPA, endothelin,
growth hormone, and estrogen to induce phosphorylation of Tyr 845. We hypothesize that c-Src-mediated phosphorylation of Tyr 845 is a central
signaling event and is required for mitogenesis to occur in response to a variety of external stimuli in addition to EGF. The signaling molecules that
transmit mitogenic cues from phosphorylated Tyr 845 have yet to be delineated, but may include such effectors as STAT5b, PI-3K, or ERK5. ER,
estrogen receptor.
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aphorylation of Tyr 845 is required for both the EGF-
induced association between STAT5b and HER1 as well
as tyrosine phosphorylation of STAT5b. These studies
suggest a model whereby HER1 and c-Src overexpres-
sion and EGF stimulation lead to the phosphorylation of
Tyr845 and the recruitment and activation of STAT5b.
A number of other signaling molecules have also been
linked to EGF-induced mitogenesis in various cell systems,
and should be considered as additional candidates for
downstream effectors of Tyr845. These signaling molecules
include PI-3K, big MAPK [BMK1 or extracellular-signal-reg-
ulated kinase (ERK)5], and the transcription factor Myc.
After growth factor activation, PI-3K interacts, through its
SH2 domain, with tyrosine phosphorylated growth factor
receptors, resulting in an increase in PI-3K activity. Studies
using specific antibodies to PI-3K [56•] demonstrated that
its catalytic activity is required for EGF (and platelet-derived
growth factor)-induced mitogenesis. Although PI-3K associ-
ates with the EGF receptor, the binding site has not been
characterized and thus it is interesting to speculate that this
function may be fulfilled by Tyr 845. ERK5, a member of the
MAPK family, was first shown to be activated in response to
oxidative stress, hyperosmolality, and serum. Recent studies
[57••,58] have shown that this kinase is also activated in
response to EGF and nerve growth factor. Furthermore,
dominant-negative ERK5 blocks EGF-induced cell prolifera-
tion in a breast epithelial cell line by preventing cells from
entering the S phase [57••]. Studies in mouse fibroblasts
have shown that c-Src kinase is required for ERK5 activa-
tion in response to hydrogen peroxide. Although a role of
c-Src in EGF activation of ERK5 has not yet been demon-
strated, these studies provide the background for a poten-
tial role of ERK5 in the c-Src-mediated activation of HER1.
One substrate of ERK5 is the early response gene c-myc
[59]. C-myc encodes a nuclear phosphoprotein, which, in
combination with Max, activates gene transcription. C-Myc
expression correlates with the proliferative state [60], and
has been shown to rescue platelet-derived growth factor
signaling that is blocked by kinase-inactive c-Src [61].
Together these findings link c-Src and EGF with PI-3K,
ERK5, and c-Myc, and are suggestive of a potential role for
one or more of these molecules to function as downstream
effectors of phosphorylated Tyr 845.
Conclusion
Substantial evidence is accumulating to indicate functional
synergism between the nonreceptor tyrosine kinase c-Src
and members of the EGF receptor family in promoting
breast cancer progression. Members of both families are
overexpressed in approximately 70% or more of human
breast cancers, and the human EGF receptor (HER1) and
HER2/neu portend a poor prognosis for the disease.
It has been demonstrated that c-Src, which is nontrans-
forming when overexpressed alone, can potentiate the
tumorigenic capacity of overexpressed HER1. Recently,
one mechanism by which c-Src synergizes with the HER1
has been uncovered. This mechanism involves the
EGF-dependent association of c-Src with HER1 and
phosphorylation of the receptor by c-Src on residues Tyr
845 and Tyr 1101. The functional consequences of Tyr
1101 phosphorylation are unknown, but phosphorylation
of Tyr 845 is required for EGF-induced DNA synthesis
and activation of members of the STAT family of transcrip-
tion factors, particularly STAT5b, but not activation of Shc
or MAPK. Whether the STATs are the predominant media-
tors of Tyr 845-dependent mitogenesis or whether there
are other mitogenic signaling pathways that emanate from
phosphorylated Tyr 845 remains to be determined. Sur-
prisingly, Tyr 845 phosphorylation has also been found to
be an intermediate in mitogenic signaling from a variety of
GPCR, as well as from certain cytokine receptors and the
estrogen receptor. Thus, HER1, and specifically phospho-
rylation of Tyr 845 by c-Src, appears to play an important,
perhaps widespread role in mediating cell responses to an
array of external signals.
c-Src also complexes with another member of the EGF
receptor family, namely HER-2 or erbB-2/neu. This associ-
ation is independent of extracellular ligand and appears to
contribute more to cell survival and anchorage-indepen-
dent growth of breast cancer cells than to anchorage-
dependent growth or migration. The mechanism of c-Src
interaction with HER2 and how this interaction may trans-
mit survival or anchorage-independent growth signals is
not known, but it is speculated to be different than the
interaction between c-Src and HER1.
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